{"filing":{"accession_number":"0001104659-26-094445","cik":"0001509745","ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tm2620947d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926094445/tm2620947d1_8k.htm"},"events":[{"id":27025,"run_id":24594,"accession_number":"0001104659-26-094445","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cypherpunk Technologies announced Q2 2026 financial results (quarter ended June 30, 2026) with net income of $39.4 million ($0.18 per diluted share), including detailed financial metrics, balance sheet data, and operational highlights. The earnings release was furnished as Exhibit 99.1.","company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28376,"accession_number":"0001104659-26-094445","item_number":"2.02","item_title":"Results","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 12, 2026. The Item 2.02 disclosure announces financial results including net income of $39.4 million ($0.18 per diluted share), with detailed financial metrics, balance sheet data, and operational highlights. The press release is furnished as Exhibit 99.1 and contains selected financial results and company highlights, which is the standard format for earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:13:41.106077+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28377,"accession_number":"0001104659-26-094445","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 8.01 disclosure centers on Leap Therapeutics' publication of Phase 2 DeFianCe study results in Clinical Cancer Research, but the primary substantive content in the attached Exhibit 99.1 is Cypherpunk Technologies' second quarter 2026 financial results announcement, including net income of $39.4 million (versus a loss in Q2 2025), ZEC treasury holdings, and operational highlights. While the Item 8.01 text emphasizes the clinical publication, the filing's core disclosure is the earnings release with financial results, balance sheet data, and business updates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:13:41.106077+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28376,"accession_number":"0001104659-26-094445","item_number":"2.02","item_title":"Results","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 12, 2026. The Item 2.02 disclosure announces financial results including net income of $39.4 million ($0.18 per diluted share), with detailed financial metrics, balance sheet data, and operational highlights. The press release is furnished as Exhibit 99.1 and contains selected financial results and company highlights, which is the standard format for earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:13:41.106077+00:00","company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","filing_date":"2026-08-12"},{"id":28377,"accession_number":"0001104659-26-094445","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 8.01 disclosure centers on Leap Therapeutics' publication of Phase 2 DeFianCe study results in Clinical Cancer Research, but the primary substantive content in the attached Exhibit 99.1 is Cypherpunk Technologies' second quarter 2026 financial results announcement, including net income of $39.4 million (versus a loss in Q2 2025), ZEC treasury holdings, and operational highlights. While the Item 8.01 text emphasizes the clinical publication, the filing's core disclosure is the earnings release with financial results, balance sheet data, and business updates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:13:41.106077+00:00","company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","filing_date":"2026-08-12"}]}